Truvestments Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Truvestments Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.13K	Sell	177 -154	-47%	-$3.35K	﹤0.01%	908
2025 Q4	$6.95K	Hold	331	–	–	﹤0.01%	748
2025 Q3	$5.09K	Sell	331 -495	-60%	-$6.48K	﹤0.01%	818
2025 Q2	$7.74K	Hold	826	–	–	﹤0.01%	683
2025 Q1	$10.1K	Sell	826 -89	-10%	-$1.25K	﹤0.01%	655
2024 Q4	$12.1K	Buy	915 +398	+77%	+$6.81K	﹤0.01%	575
2024 Q3	$9.95K	Buy	+517	New	+$10.7K	﹤0.01%	584
2024 Q2	–	Sell	-218	Closed	-$5.19K	–	616
2024 Q1	$5.19K	Hold	218	–	–	﹤0.01%	551
2023 Q4	$4.71K	Hold	218	–	–	﹤0.01%	604
2023 Q3	$3.17K	Hold	218	–	–	﹤0.01%	556
2023 Q2	$4.56K	Hold	218	–	–	﹤0.01%	536
2023 Q1	$4.6K	Buy	+218	New	+$5.42K	﹤0.01%	521

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Truvestments Capital's SNDX Position: Q1 2026 in Review

Truvestments Capital reduced its Syndax Pharmaceuticals (SNDX) stake by 47% in Q1 2026, selling an estimated $3.35K and leaving 177 shares worth $4.13K. The position accounts for ﹤0.01% of the portfolio, ranked #908.

Truvestments Capital first reported a position in SNDX in Q1 2023 and has held it in 12 quarters since. The position peaked at $12.1K in Q4 2024. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

Truvestments Capital held 177 shares of Syndax Pharmaceuticals worth $4.13K as of Q1 2026.
Truvestments Capital sold 154 Syndax Pharmaceuticals shares in Q1 2026, an estimated $3.35K.
Syndax Pharmaceuticals made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #908 holding.
Truvestments Capital first reported a position in Syndax Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
Truvestments Capital's Syndax Pharmaceuticals position peaked at $12.1K in Q4 2024.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.